Interpretation of PET Scans: Do Not Take SUVs at Face Value
To read more click here Weiss G.J. and Korn R.L. “Interpretation of PET Scans: Do Not Take SUVs at Face Value.” J Thor Onc., 7(12): 1744-45, (2012).
Metastatic Basal Cell Carcinoma in the Era of Hedgehog Signaling Pathway Inhibitors
BACKGROUND: Inhibition of the hedgehog signaling pathway (HHSP) for the treatment of locally advanced basal cell carcinoma (BCC) and metastatic BCC (mBCC) has produced promising results. Typically, mBCC is not taken into consideration during the workup of a patient with… Read More
18-FDG PET/CT assessment of basal cell carcinoma with Vismodegib Inhibitors
Abstract The use of 18-fluorodeoxyglucose (FDG) positron emission tomography with computed tomography (PET/CT) in subjects with advanced basal cell carcinoma (BCC) has not been fully explored due to the rarity of disease presentation. This study evaluated PET/CTs from subjects with… Read More
The Clinical Research Center: A Vital Part of the ACR Mission
The ACR’s mission statement identifies five pillars of excellence. One of its pillars is research. ACR is recognized by many as supporting one of the premier research endeavors sponsored by a professional medical society of which the ACR Clinical Research… Read More
Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
Purpose The trial objectives were to identify the maximum-tolerated dose (MTD) of first-line gemcitabine plus nab-paclitaxel in metastatic pancreatic adenocarcinoma and to provide efficacy and safety data. Additional objectives were to evaluate positron emission tomography (PET) scan response, secreted protein… Read More
